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Since the discovery of penicillin, antibiotics had been of critical importance in the control of 
infectious diseases. However, the extensive use and misuse of antibiotics during the last decades 
led to the wide development and spread of multiple drug resistance in bacteria. Associated to the 
alarming levels of antibiotic resistances and the difficulty to discover novel antibiotics, the re-
emergence of infectious diseases poses new challenges. We are probably close to reach the end of 
the antibiotics period and researchers are now investigating alternatives to treat infectious 
diseases. Contrarily to traditional strategies that aim to kill bacteria or prevent their growth, these 
new approaches intend to block the ability of bacteria to harm the host and are thought to apply 
less selective pressure limiting the development of bacterial resistance. These emerging strategies 
that seek to directly inhibit bacterial virulence factors, benefit from the detailed knowledge of the 
functional and molecular mechanisms underlying key pathogenic determinants acquired during 
the last decades of research in host-pathogen interactions [1]. In particular, bacterial toxins are 
primary targets for these novel anti-virulence strategies. In this issue of The Journal of Infectious 
Diseases, Wang and colleagues show that fisetin, a natural flavonoid with negligible 
antimicrobial activity, has an effective anti-virulence activity against Listeria monocytogenes by 
directly interfering with a bacterial secreted toxin. 
 
Listeria monocytogenes (Lm) is a facultative intracellular human food-borne pathogen that causes 
listeriosis, an infection characterized by gastroenteritis, meningitis, encephalitis and maternofetal 
infections. Listeriosis is the most frequent cause of death due to the consumption of contaminated 
food in Europe, and is the third foodborne infection in terms of cost of illness and quality life 
losses [2, 3]. Lm enters the host via the ingestion of contaminated foods, invades the intestine, 
translocates to mesenteric lymph nodes and spreads to the liver, spleen, brain and to the placenta. 
During infection, Lm has the ability to cross the intestinal, the blood-brain and the placental 
barriers, entering, surviving and multiplying inside phagocytic and non-phagocytic cells [4]. To 
establish and sustain infection Lm employs an arsenal of virulence factors to hijack host-signaling 
pathways [5, 6]. While remaining a real public health concern, Lm has emerged as an exceptional 
model to address the different facets of host-pathogen interactions and the design of new 
therapeutic strategies. 
Listeriolysin O (LLO) is a crucial virulence factor produced by Lm [7]. It is a pore-forming toxin 
(PFT) member of the cholesterol dependent cytolysins (CDC) family [8]. LLO monomers are 
secreted by the bacteria and oligomerize at the surface of target cell into a ring [9]. Membrane 
insertion of LLO results in ion fluxes across damaged membranes and ultimately leads to cell 
lysis in conditions of extensive damage and/or inefficient membrane repair mechanisms [10]. 
Inactivation of LLO results in the inability of Lm to escape from the internalization vacuole 
thereby decreasing the Lm virulence potential [11, 12]. Besides membrane lysis, it has become 
recently apparent that LLO acting from the intracellular or extracellular milieu exerts additional 
effects on the host cell [7]. Intracellular LLO affects host cell signaling [13, 14], induces 
autophagy [15] and suppresses reactive oxygen species [16]. LLO was also shown to deregulate 
host SUMOylation [17], to induce endoplasmic reticulum stress [18] and mitochondria 
fragmentation [19], and to promote regulatory epigenetic changes [20]. 
 
A previous study showed that sub-inhibitory concentrations of plant essential oils could inhibit 
LLO activity and decrease Lm virulence, however the specific compound responsible for this 
effect remained unknown [21]. In this issue of The Journal of Infectious Diseases, Wang and 
colleagues report the discovery of the natural flavonoid fisetin as an effective anti-virulence agent 
against LLO activity. They showed that fisetin inhibits the hemolysis capacity of LLO and is able 
to protect mice from lethal infection by Lm. Molecular modeling studies revealed that fisetin 
directly engages LLO, causing a conformational shift of the LLO domains critical for its binding 
to cholesterol and oligomerization. Coupling mutational and biochemical approaches they 
identified LLO amino acid residues involved in the sensitivity to fisetin. 
This work thus establishes fisetin as a novel anti-virulence compound that targets LLO by a 
unique mechanism, counteracting toxin binding to host cells and oligomerization. Interestingly, 
fisetin is able to decrease Lm virulence in tissue-cultured cells and animal infection models, 
without affecting the Lm growth or the phagocytic capacity of macrophages. Notably, while new 
roles have been frequently assigned to LLO, this study supports that, during in vivo infection, 
pore formation remains its main function. 
 
Anti-virulence strategies targeting bacterial toxins to prevent their deleterious effects were 
previously developed. Such approaches were based in the use of soluble analogues or specific 
antibodies against toxins, thereby preventing their interaction with their receptors at the host cell 
membrane. Alternatively, they aim at blocking toxin pores using synthetic compounds [1]. In the 
case of LLO, neutralizing monoclonal antibodies were previously described to control Lm 
intracellular growth and virulence [22]. However, one important caveat is that these strategies are 
often associated to high costs of production and maintenance. By the contrary, Fisetin is present 
in many fruits and vegetables being associated to low costs of production, and was shown to have 
broad biological properties ranging from antioxidative to cancer therapeutic effects. The 
bioavailability and toxicity of fisetin are also well established [23]. In addition, an important 
advantage with dietary plant flavonoids is that they are perceived as non-toxic and have wide 
human acceptance [24]. This study thus pave the way for the development of broad anti-virulence 
approaches based on natural products. Importantly, as CDCs generally present structural 
homologies, it would be interesting to test the effect of fisetin on CDCs produced by other 
bacterial pathogens like Streptococcus pyogenes and pneumoniae, Arcanobacterium pyogenes or 
Clostridium perfringens [25]. Indeed, an optimal therapeutic agent would target virulence factors 
present in several pathogens. Results presented by Wang and colleagues associated to the recent 
determination of the LLO crystal structure [26] could allow the generation of fisetin derivatives 
with improved activity against CDCs. 
 
Due to their rapid evolution rate, bacteria are experts in finding alternative routes to achieve 
growth and infection. Most virulence traits being not essential for bacterial survival, therapeutic 
strategies based on the inhibition of virulence should apply mild evolutionary pressure and limit 
the development of resistance. These promising approaches are sought to dampen pathogen 
progression allowing the control of infection through an effective host immune response or 
increasing the efficacy of classic therapies targeting bacterial growth. Indeed, in the presence of 
anti-virulence compounds bacteria can still grow and produce the targeted virulence determinants, 
being able to injure again the host in the absence of such inhibitors. It is thus probably coupled 
with traditional antibiotics that anti-virulence therapies will bring an undeniably advantage in the 
fight against infectious diseases. 
 
While resistance development and side effects on the host including microbiota are always 
possible, this work by Wang and colleagues opens new perspectives for natural compounds as 
effective anti-virulence strategies against human bacterial pathogens. 
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